Precision Biosciences (DTIL) Change in Receivables (2018 - 2026)
Precision Biosciences' (DTIL) quarterly Change in Receivables came in at $4.0 million in Q1 2026, up 1877.78% year-on-year from $202247.2 in Q1 2025, and up 100100.0% on a QoQ basis from -$4000.0 in Q4 2025.
Precision Biosciences (DTIL) Change in Receivables (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Change in Receivables data on file, last reported at $4.0 million in Q1 2026.
- On a quarterly basis, Change in Receivables rose 1877.78% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 1135.23% increase from a year earlier, with the FY2025 full-year figure at -$229000.0, up 65.92% from the prior year.
- Change in Receivables for Q1 2026 stood at $4.0 million, up from -$4000.0 in the prior quarter.
- Over the last five years, Change in Receivables for DTIL reached as high as $4.0 million in Q1 2026 and fell as low as -$49.8 million in Q3 2022.
- Historically, Change in Receivables has averaged -$3.1 million across 5 years, with a median of -$19000.0 in 2024.
- Across the five-year window, Change in Receivables slumped 51940.0% in 2023 and soared 1877.78% in 2026, its largest moves.
- Year by year, Change in Receivables stood at $5000.0 in 2022, then slumped by 51940.0% to -$2.6 million in 2023, then soared by 101.58% to $41000.0 in 2024, then sank by 109.76% to -$4000.0 in 2025, then surged by 100100.0% to $4.0 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $4.0 million in Q1 2026, -$4000.0 in Q4 2025, and $4000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Precision Biosciences | 182.42 Mn | 154.13 Mn | - | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Jun 30, 2024 | -183,000.00 |
| Jun 30, 2024 | -183,000.00 |
| Mar 31, 2024 | -511,000.00 |
| Mar 31, 2024 | -511,000.00 |
| Dec 31, 2023 | -2.59 Mn |
| Dec 31, 2023 | -2.59 Mn |